AKT1 and non-small cell lung carcinoma: This suggest that therapeutic combinations able to synergistically inhibit both Raf/MEK/ERK and PI3K/AKT effector signaling should overcome YAP-dependent senescence and treat EGFR-mutated NSCLC.